Subgroup analyses in randomized clinical trials: Value and limitations Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy.

[1]  H. Schunkert,et al.  Ticagrelor or Prasugrel in Patients With Acute Coronary Syndromes and Diabetes Mellitus. , 2020, JACC. Cardiovascular interventions.

[2]  J. McMurray,et al.  Dapagliflozin in Patients with Chronic Kidney Disease. , 2020, The New England journal of medicine.

[3]  G. Hankey,et al.  Colchicine in Patients with Chronic Coronary Disease. , 2020, The New England journal of medicine.

[4]  G. Lip,et al.  Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation. , 2020, The New England journal of medicine.

[5]  P. Ponikowski,et al.  Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. , 2020, The New England journal of medicine.

[6]  Jennifer L. Bell,et al.  Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report , 2020, medRxiv.

[7]  Deepak L. Bhatt,et al.  THEMIS and THEMIS-PCI. , 2019, European heart journal.

[8]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[9]  Deepak L. Bhatt,et al.  Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. , 2019, Lancet.

[10]  W. Rottbauer,et al.  Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. , 2019, The New England journal of medicine.

[11]  Deepak L. Bhatt,et al.  Ticagrelor in Patients with Stable Coronary Disease and Diabetes. , 2019, The New England journal of medicine.

[12]  Akshay S. Desai,et al.  Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. , 2019, The New England journal of medicine.

[13]  M. Sabatine,et al.  2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. , 2019, European heart journal.

[14]  W. E. Sanabria,et al.  Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial , 2019, The Lancet.

[15]  B. Lewis,et al.  The age of RCT`s 3 Important Aspects of RCT`s in Cardiovascular Pharmacotherapy with examples from Lipid and Diabetes Trials. , 2019, European heart journal. Cardiovascular pharmacotherapy.

[16]  Declare–Timi Investigators.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019 .

[17]  P. Raggi,et al.  Baseline low-density lipoprotein cholesterol to predict the extent of cardiovascular benefit from lipid-lowering therapies: a review , 2018, European heart journal. Cardiovascular pharmacotherapy.

[18]  Deepak L. Bhatt,et al.  Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome , 2018, New England Journal of Medicine.

[19]  Catherine R. Lesko,et al.  Considerations when assessing heterogeneity of treatment effect in patient-centered outcomes research. , 2018, Journal of clinical epidemiology.

[20]  J. Ferreira,et al.  Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease: systematic review and meta-analysis , 2018, European heart journal. Cardiovascular pharmacotherapy.

[21]  Marc P. Bonaca,et al.  Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) , 2017, Circulation.

[22]  A. Keech,et al.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.

[23]  S. Pocock,et al.  The Primary Outcome Is Positive - Is That Good Enough? , 2016, The New England journal of medicine.

[24]  John B Buse,et al.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. , 2016, The New England journal of medicine.

[25]  A. Shenker,et al.  Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban , 2016, Journal of clinical pharmacology.

[26]  C. Grady,et al.  Detection and Management of Geographic Disparities in the TOPCAT Trial , 2016, JACC. Basic to translational science.

[27]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[28]  M. Pencina,et al.  Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. , 2015, The New England journal of medicine.

[29]  Improve-It Investigators.  Ezetimibe added to statin therapy after acute coronary syndromes , 2015 .

[30]  R. Califf,et al.  Prevalence, characteristics, and predictors of early termination of cardiovascular clinical trials due to low recruitment: insights from the ClinicalTrials.gov registry. , 2014, American heart journal.

[31]  Guideline on the investigation of subgroups in confirmatory clinical trials , 2014 .

[32]  M. Keltai,et al.  Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. , 2012, European heart journal.

[33]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[34]  Stephen W Lagakos,et al.  Statistics in medicine--reporting of subgroup analyses in clinical trials. , 2007, The New England journal of medicine.